Syneos Health, KX Partner to Advance Data-Driven Transformation in Biopharmaceutical Asset Development
By Alex Keown
March 22, 2023
Biopharmaceutical solutions company Syneos Health has forged a strategic, data-driven predictive analytics partnership with New York-based KX, the maker of analytics engine kdb, to create a new class of data and AI management engine.
The collaboration between the two companies is expected to provide customers with data-driven predictive analytics, AI and machine learning (ML) capabilities. The partnered companies believe these capabilities will enable customers to “address complex healthcare decisions” through Data Timehouse, what the companies called “a new class of data and AI management engine.”
Data Timehouse is designed for temporal data that is generated by digital transformation. Benefits include real-time engagement and faster and more accurate decision-making related to drug trial site selection, the companies said.
Syneos said the collaboration with KX will improve clinical trial efficiency, reduce costs and speed time to market for life-changing therapies for patients. Additionally, it will enable customers in the biopharmaceutical industry to harness the power of big data in order to solve complex healthcare decisions.
Baba Shetty, president of technology and data solutions for Morrisville-based Syneos Health, said the partnership with KX will enable the company to advance its “ability to data-driven insights and AI-enabled solutions” that will allow clients to solve clinical development and commercialization issues.
“We’ve seen first-hand with multiple customers the ability of KX to dramatically accelerate the most challenging computational challenges with massive data sets, supporting use cases including patient simulations (QSP) for clinical and omnichannel/Real World Evidence for commercial,” Shetty said in a statement.
Syneos’ partnership with KX comes days after the company entered into a collaboration with Microsoft to leverage AI-ready technology that will accelerate asset development and optimize performance. The partnership harnesses the capabilities of Microsoft Azure services and pairs it with Syneos’ advanced analytics platform to support the analysis, design and execution of clinical trials and commercial programs across the globe.
In its announcement earlier this week, Syneos said AI-enabled platform will be able to “process and analyze data to fast-track timelines, optimize resource allocation and unlock clinical trial efficiencies.” This will allow for enhanced site selection and reduced enrollment timelines to bring new treatments to patients faster, the company added.
Last year, Syneos partnered with Datavant to harness the capabilities of that company’s Switchboard technology in order to develop advanced analytics and AI-driven technologies for more efficient clinical trials.
The partnership with KX amplifies the collaboration with Microsoft, Syneos said. KX uses Microsoft’s Azure technology to support its own platform.
“Our Data Timehouse leverages the power of data analytics and AI to enable faster execution of clinical trials and discovery of new drug treatments, ultimately increasing the likelihood of any given trial’s success,” Ashok Reddy, chief executive officer at KX said in a statement.
- About the Author
- Latest Posts
Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.
